Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xencor, Inc. - Common Stock (NQ:XNCR)

8.970 -0.100 (-1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Xencor to Present at Upcoming Investor Conferences
From Xencor, Inc.
Via Business Wire
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor Reports Third Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
From Xencor, Inc.
Via Business Wire
Xencor's Return On Capital Employed Overview
  
Via Benzinga
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
Xencor Earnings Preview
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report an... 
Via Benzinga
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
From Xencor, Inc.
Via Business Wire
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
From Xencor, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
Xencor Appoints Nancy Valente, M.D., to Board of Directors
From Xencor, Inc.
Via Business Wire
Xencor Reports Second Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 422 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. 
Via InvestorPlace
Xencor Reports First Quarter 2022 Financial Results
From Xencor, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. 
Via Benzinga
Xencor's Earnings Outlook
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Xencor will report... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
From Xencor, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.